OR WAIT null SECS
ViiV Healthcare has presented three-year clinical trial, reinforcing that the two-drug regimen Dovato can be used as a viable switch option for people living with HIV.
Global specialist HIV company, ViiV Healthcare, has presented three-year data from the TANGO study, which further reinforce that the two-drug regimen (2DR) Dovato (dolutegravir/lamivudine) can be used as a viable switch option for people living with HIV.
The results, which were reported in a Sep. 29, 2021 press release, demonstrated that the 2DR Dovato continued to display non-inferior efficacy and a high barrier to resistance compared to continuation of tenofovir alafenamide fumarate (TAF)-based regimens of at least three drugs in virologically suppressed adults living with HIV-1 who have not experienced prior virologic failure. There were no instances of confirmed virologic failure in the dolutegravir/lamivudine arm of the study, whereas there were three instances in the TAF-based regimen.
“These data provide us with further long-term evidence that switching virologically suppressed people living with HIV from TAF-based 3-drug regimens to dolutegravir/lamivudine will not only maintain virologic suppression, but offers a treatment option consisting of fewer medicines,” said Olayemi Osiyemi, MD, founder, CEO, and president of Triple O Medical Services and Triple O Research Institute PA, United States, lead author and one of the investigators of the TANGO study, in the press release. “As we now consider HIV a long-term condition requiring life-long medication, these results give physicians the data they need to have more confidence in switching their virologically suppressed patients who are taking three or more medicines. Additionally, these data show no confirmed virologic failures, which is important over a long-term study.”
“The latest results from the TANGO study further reinforce Dovato’s role in the HIV treatment landscape, allowing people living with HIV to maintain virologic suppression over the long-term with fewer medicines,” added Kimberly Smith, MD, MPH, head of Research & Development at ViiV Healthcare, in the press release.
ViiV Healthcare is majority owned by GlaxoSmithKline, with Pfizer and Shionogi as shareholders. Dovato is a once-daily, single-pill, 2DR that is approved for use in the US, Europe, Japan, Australia, and other countries worldwide.